Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
04 2020
Historique:
received: 12 07 2019
revised: 03 10 2019
accepted: 07 02 2020
pubmed: 13 2 2020
medline: 11 11 2020
entrez: 13 2 2020
Statut: ppublish

Résumé

High-grade serous ovarian cancer (HGSC), the principal cause of death from gynecologic malignancies in the world, has not significantly benefited from advances in cancer immunotherapy. Although HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is unknown. The goal of this study was to establish the global landscape of HGSC tumor-specific antigens (TSA) using a mass spectrometry pipeline that interrogated all reading frames of all genomic regions. In 23 HGSC tumors, we identified 103 TSAs. Classic TSA discovery approaches focusing only on mutated exonic sequences would have uncovered only three of these TSAs. Other mutated TSAs resulted from out-of-frame exonic translation (

Identifiants

pubmed: 32047025
pii: 2326-6066.CIR-19-0541
doi: 10.1158/2326-6066.CIR-19-0541
doi:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

544-555

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Qingchuan Zhao (Q)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Jean-Philippe Laverdure (JP)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Joël Lanoix (J)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Chantal Durette (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Caroline Côté (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Éric Bonneil (É)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Céline M Laumont (CM)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Patrick Gendron (P)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Krystel Vincent (K)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Mathieu Courcelles (M)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Sébastien Lemieux (S)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
Department of Computer Science and Operations Research, Université de Montréal, Montreal, Quebec, Canada.

Douglas G Millar (DG)

Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Pamela S Ohashi (PS)

Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Department of Medical Biophysics and Immunology, University of Toronto, Toronto, Ontario, Canada.

Pierre Thibault (P)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada. claude.perreault@umontreal.ca pierre.thibault@umontreal.ca.
Department of Chemistry, Université de Montréal, Montreal, Quebec, Canada.

Claude Perreault (C)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada. claude.perreault@umontreal.ca pierre.thibault@umontreal.ca.
Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH